Kymera Therapeutics, Inc. (KYMR)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Nello Mainolfi
Employees:
55
300 TECHNOLOGY SQUARE, 2ND FLOOR, CAMBRIDGE, MA 02139
857-285-5314

We are a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.

Data derived from most recent annual or quarterly report
Market Cap 2.824 Billion Shares Outstanding51.04 Million Avg 30-day Volume 263.685 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 91.92 / 29.93 Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from KYMR instead.

View recent insider trading info

Funds Holding KYMR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KYMR BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

91.8 Thousand total shares from 11 transactions

Exercise Derivative Conversion (M)

91.8 Thousand total shares from 4 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MAINOLFI NELLO CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
992,304 2021-10-08 16

JACOBS BRUCE N. CHIEF FINANCIAL OFFICER

  • Officer
217,155 2021-09-03 7

CHESWORTH RICHARD CHIEF SCIENTIFIC OFFICER

  • Officer
263,340 2021-08-27 3

BOOTH BRUCE

  • Director
6,875,698 2021-08-11 3

ATLAS VENTURE ASSOCIATES X, L.P.

ATLAS VENTURE ASSOCIATES X, LLC

  • 10% Owner
5,763,012 2021-08-11 2

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BVF I GP LLC

BIOTECHNOLOGY VALUE FUND II LP

BVF II GP LLC

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF GP HOLDINGS LLC

BVF INC/IL

LAMPERT MARK N

  • Director
  • SEE REMARKSSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
268,728 2021-07-01 2

CAUGHEY ELAINE CHIEF BUSINESS OFFICER

  • Officer
100,000 2021-06-21 2

HOROBIN JOANNA

  • Director
20,063 2021-06-16 1

HALL STEVEN EDWARD

  • Director
20,063 2021-06-16 1

ALBERS JEFFREY W.

  • Director
20,063 2021-06-16 1

ESPOSITO PAMELA

  • Director
20,063 2021-06-16 1

RIDLOFF ELENA

  • Director
20,063 2021-06-16 3

NICHOLSON DONALD WILLIAM

  • Director
20,063 2021-06-16 1

HRUSTANOVIC GORJAN

  • Director
20,063 2021-06-16 1

ATLAS VENTURE FUND X, L.P.

  • 10% Owner
5,763,012 2021-05-18 2

GOLLOB JARED CHIEF MEDICAL OFFICER

  • Officer
215,413 2021-03-11 4

REDMILE GROUP, LLC

GREEN JEREMY

  • 10% Owner
No longer subject to file 2020-08-25 0

ATLAS VENTURE FUND X, L.P.

ATLAS VENTURE ASSOCIATES X, LLC

ATLAS VENTURE ASSOCIATES X, L.P.

ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.

ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC

ATLAS VENTURE OPPORTUNITY FUND I, L.P.

  • 10% Owner
9,061,668 2020-08-25 2

ALEXANDRIA VENTURE INVESTMENTS, LLC

  • 10% Owner
No longer subject to file 2020-08-25 0

WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P.

  • 10% Owner
No longer subject to file 2020-08-25 0

HEDIN ANDREW

  • Director
40,127 2020-08-20 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

MAINOLFI NELLO - Director - Officer CHIEF EXECUTIVE OFFICER

2021-10-12 16:30:47 -0400 2021-10-11 M 6,456 $2.08 a 470,655 direct 6.6679 -2.1606 6.6679 2 -2.1606 6

MAINOLFI NELLO - Director - Officer CHIEF EXECUTIVE OFFICER

2021-10-12 16:30:47 -0400 2021-10-11 S 744 $54.50 d 464,199 direct yes 6.6679 -2.1606 6.6679 2 -2.1606 6

MAINOLFI NELLO - Director - Officer CHIEF EXECUTIVE OFFICER

2021-10-12 16:30:47 -0400 2021-10-11 M 6,456 d 28,725 direct

MAINOLFI NELLO - Director - Officer CHIEF EXECUTIVE OFFICER

2021-10-12 16:30:47 -0400 2021-10-11 S 5,712 $53.58 d 464,943 direct yes 6.6679 -2.1606 6.6679 2 -2.1606 6

MAINOLFI NELLO - Director - Officer CHIEF EXECUTIVE OFFICER

2021-10-12 16:30:47 -0400 2021-10-08 M 41,544 d 35,181 direct

MAINOLFI NELLO - Director - Officer CHIEF EXECUTIVE OFFICER

2021-10-12 16:30:47 -0400 2021-10-08 S 7,920 $59.28 d 465,140 direct yes 6.6679 -2.1606 6.6679 2 -2.1606 6

MAINOLFI NELLO - Director - Officer CHIEF EXECUTIVE OFFICER

2021-10-12 16:30:47 -0400 2021-10-08 S 21,236 $55.56 d 484,507 direct yes 6.6679 -2.1606 6.6679 2 -2.1606 6

MAINOLFI NELLO - Director - Officer CHIEF EXECUTIVE OFFICER

2021-10-12 16:30:47 -0400 2021-10-08 S 271 $61.87 d 464,199 direct yes 6.6679 -2.1606 6.6679 2 -2.1606 6

MAINOLFI NELLO - Director - Officer CHIEF EXECUTIVE OFFICER

2021-10-12 16:30:47 -0400 2021-10-08 S 2,078 $57.29 d 473,060 direct yes 6.6679 -2.1606 6.6679 2 -2.1606 6

MAINOLFI NELLO - Director - Officer CHIEF EXECUTIVE OFFICER

2021-10-12 16:30:47 -0400 2021-10-08 M 41,544 $2.08 a 505,743 direct 6.6679 -2.1606 6.6679 2 -2.1606 6

MAINOLFI NELLO - Director - Officer CHIEF EXECUTIVE OFFICER

2021-10-12 16:30:47 -0400 2021-10-08 S 670 $60.32 d 464,470 direct yes 6.6679 -2.1606 6.6679 2 -2.1606 6

MAINOLFI NELLO - Director - Officer CHIEF EXECUTIVE OFFICER

2021-10-12 16:30:47 -0400 2021-10-08 S 9,369 $56.82 d 475,138 direct yes 6.6679 -2.1606 6.6679 2 -2.1606 6

JACOBS BRUCE N. - Officer CHIEF FINANCIAL OFFICER

2021-09-03 17:57:15 -0400 2021-09-03 S 1,500 $60.50 d 7,256 direct yes -0.7748 -0.1107 -12.6502 5.408 4 -16.556 25

JACOBS BRUCE N. - Officer CHIEF FINANCIAL OFFICER

2021-09-03 17:57:15 -0400 2021-09-03 S 8,500 $60.05 d 8,756 direct yes -0.7748 -0.1107 -12.6502 5.408 4 -16.556 25

JACOBS BRUCE N. - Officer CHIEF FINANCIAL OFFICER

2021-09-03 17:57:15 -0400 2021-09-03 A 10,000 d 209,899 direct

JACOBS BRUCE N. - Officer CHIEF FINANCIAL OFFICER

2021-09-03 17:57:15 -0400 2021-09-03 M 10,000 $2.08 d 17,256 direct -0.7748 -0.1107 -12.6502 5.408 4 -16.556 25

CHESWORTH RICHARD - Officer CHIEF SCIENTIFIC OFFICER

2021-08-27 16:55:43 -0400 2021-08-27 M 33,779 $20.00 a 33,779 direct 1.6688 3.4686 -13.3999 9.0641 9 -13.6616 30

CHESWORTH RICHARD - Officer CHIEF SCIENTIFIC OFFICER

2021-08-27 16:55:43 -0400 2021-08-27 M 33,779 d 263,340 direct

CHESWORTH RICHARD - Officer CHIEF SCIENTIFIC OFFICER

2021-08-27 16:55:43 -0400 2021-08-27 S 33,779 $60.12 d 0 direct yes 1.6688 3.4686 -13.3999 9.0641 9 -13.6616 30

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
KYMERA THERAPEUTICS INC KYMR 2021-10-26 22:15:03 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 21:45:03 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 21:15:03 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 20:45:03 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 20:15:03 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 19:45:03 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 19:15:03 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 18:45:03 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 18:15:03 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 17:45:03 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 17:15:03 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 16:45:04 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 16:15:03 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 15:45:03 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 15:15:03 UTC -0.3838 0.4538 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 14:45:03 UTC -0.3598 0.4298 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 14:15:05 UTC -0.3598 0.4298 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 13:45:03 UTC -0.3598 0.4298 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 13:15:03 UTC -0.3598 0.4298 350000
KYMERA THERAPEUTICS INC KYMR 2021-10-26 12:45:03 UTC -0.3598 0.4298 350000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund KYMR -6524.0 shares, $-392614.32 2021-07-31 N-PORT

Elevate your investments